

July 15, 2022

**To**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers, 25th Floor,  
Dalal Street, Mumbai - 400 001  
Scrip Code: 524558

Neuland Laboratories Limited  
11th Floor, (5th Office Level),  
Phoenix IVY Building,  
Plot No. 573A-III, Road No.82,  
Jubilee Hills, Hyderabad-500033,  
Telangana, India

Tel : 040 67611600 / 67611700  
Email : neuland@neulandlabs.com  
www.neulandlabs.com

Dear Sir/ Madam,

**Sub: Clarification on spurt in volume of shares traded**  
**Ref: Your Email dated July 15, 2022 - L/SURV/ONL/PV/MS/ 2022-2023 / 111**

We refer to the afore-mentioned email seeking clarification on spurt in volume of shares of the Company traded across Exchanges, in the recent past.

We would like to reiterate that our Company has been disclosing and will continue to disclose all the necessary information's/disclosures in accordance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, within the stipulated timelines and has not withheld any material information/event that in our opinion would have a bearing on the volume behavior in our scrip.



Further, we request you to note that the equity shares of the Company are freely traded on the Stock Exchanges and the Company will not be in a position to comment on the movement of shares traded on the Exchanges.

We would like to reiterate that our Company is committed to compliance with the Listing Regulations and any information, likely to have bearing on the shares traded would be disclosed to the stock exchanges from time to time.

This is for your information and records.

Thanking you

Yours Sincerely,  
For Neuland Laboratories Limited



**Sarada Bhamidipati**  
Company Secretary & Compliance Officer